The latest price target for Tonix Pharmaceuticals (NASDAQ:TNXP) was reported by Noble Capital Markets on March 20, 2025. The analyst firm set a price target for $70.00 expecting TNXP to rise to within 12 months (a possible 422.00% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Tonix Pharmaceuticals (NASDAQ:TNXP) was provided by Noble Capital Markets, and Tonix Pharmaceuticals reiterated their outperform rating.

There is no last upgrade for Tonix Pharmaceuticals

There is no last downgrade for Tonix Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tonix Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tonix Pharmaceuticals was filed on March 20, 2025 so you should expect the next rating to be made available sometime around March 20, 2026.

While ratings are subjective and will change, the latest Tonix Pharmaceuticals (TNXP) rating was a reiterated with a price target of $70.00 to $70.00. The current price Tonix Pharmaceuticals (TNXP) is trading at is $13.41, which is out of the analyst’s predicted range.